Renaissance Technologies's ADMA Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 1.53 M shares of ADMA Biologics, Inc. (ADMA) worth $27.96 M, representing 0.04% of the portfolio. First purchased in 2017-Q2, this long-term strategic position has been held for 25 quarters.
Based on 13F filings, Renaissance Technologies has maintained a strategic position in ADMA, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2024, adding 1.09 M shares. Largest reduction occurred in Q4 2025, reducing 1.24 M shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's ADMA Biologics (ADMA) Holding Value Over Time
Track share changes against reported price movement
Quarterly ADMA Biologics (ADMA) Trades by Renaissance Technologies
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -1.24 M | Reduce 44.68% | 1.53 M | $18.24 |
| Q3 2025 | -375,611 | Reduce 11.94% | 2.77 M | $14.66 |
| Q2 2025 | -402,935 | Reduce 11.35% | 3.15 M | $18.21 |
| Q1 2025 | -220,900 | Reduce 5.86% | 3.55 M | $19.84 |
| Q4 2024 | +102,692 | Add 2.80% | 3.77 M | $17.15 |
| Q3 2024 | +1.09 M | Add 42.02% | 3.67 M | $19.99 |
| Q2 2024 | +575,100 | Add 28.65% | 2.58 M | $11.18 |
| Q1 2024 | +949,100 | Add 89.71% | 2.01 M | $6.60 |
| Q4 2023 | -338,620 | Reduce 24.25% | 1.06 M | $4.52 |
| Q3 2023 | +182,820 | Add 15.06% | 1.4 M | $3.58 |
| Q2 2023 | +240,500 | Add 24.71% | 1.21 M | $0.00 |
| Q1 2023 | +277,300 | Add 39.85% | 973,235 | $0.00 |
| Q4 2022 | +57,535 | Add 9.01% | 695,935 | $0.00 |
| Q3 2022 | -87,100 | Reduce 12.01% | 638,400 | $2.43 |
| Q2 2022 | +198,800 | Add 37.74% | 725,500 | $1.98 |
| Q1 2022 | +177,800 | Add 50.96% | 526,700 | $1.83 |
| Q4 2021 | +113,900 | Add 48.47% | 348,900 | $1.41 |
| Q3 2021 | +59,374 | Add 33.81% | 235,000 | $1.13 |
| Q2 2021 | +175,626 | New Buy | 175,626 | $1.60 |
| Q4 2018 | -188,300 | Sold Out | 0 | $0.00 |
| Q3 2018 | +159,100 | Add 544.86% | 188,300 | $6.21 |
| Q2 2018 | +29,200 | New Buy | 29,200 | $4.52 |
| Q4 2017 | -20,300 | Sold Out | 0 | $0.00 |
| Q3 2017 | +9,000 | Add 79.65% | 20,300 | $3.10 |
| Q2 2017 | +11,300 | New Buy | 11,300 | $3.72 |
Renaissance Technologies's ADMA Biologics Investment FAQs
Renaissance Technologies first purchased ADMA Biologics, Inc. (ADMA) in Q2 2017, acquiring 11,300 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held ADMA Biologics, Inc. (ADMA) for 25 quarters since Q2 2017.
Renaissance Technologies's largest addition to ADMA Biologics, Inc. (ADMA) was in Q3 2024, adding 3,667,196 shares worth $73.31 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 1,532,621 shares of ADMA Biologics, Inc. (ADMA), valued at approximately $27.96 M.
As of the Q4 2025 filing, ADMA Biologics, Inc. (ADMA) represents approximately 0.04% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies's peak holding in ADMA Biologics, Inc. (ADMA) was 3,769,888 shares, as reported at the end of Q4 2024.